{"entity":{"id":"nct06332092","kind":"trial","name":"FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of FID007 in head and neck squamous cell carcinoma, run by Fulgent Pharma LLC., active and no longer recruiting.","summary":"FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06332092 by Fulgent Pharma LLC., with 46 participants enrolled, started 2024-04-10 and due to reach its primary completion in 2025-12-31. Interventions recorded: FID007.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06332092","url":"https://clinicaltrials.gov/study/NCT06332092"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06332092","phase":"2","setting":"A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma","sponsor":"Fulgent Pharma LLC.","enrolled":46,"outcomes":[]},"route":"/trials/nct06332092/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}]}}